| Using the Diagnostic Assessment of the Severely Handicapped-II (DASH-II) to measure the therapeutic effects of risperidone. | |
| | |
MedLine Citation:
|
PMID: 14675232 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Within the scope of a double-blind, placebo-controlled, crossover medication study, the Diagnostic Assessment of the Severely Handicapped-II (DASH-II) was evaluated as a measurement for determining the effectiveness of the medication risperidone in treating the problem behaviour of 21 people with intellectual disabilities (ID). METHOD: Participants' caregivers completed the DASH-II during the placebo/baseline phase of the study and the maintenance phase of the study, and completed the Aberrant Behavior Checklist - Community (ABC-C) weekly throughout the entire study. The results obtained using the DASH-II were compared to those obtained using the ABC-C, an instrument shown to be well correlated with the DASH-II. RESULTS: Results suggest that while the DASH-II and the ABC-C were well correlated during the placebo/baseline phase of the current study, they were not well correlated at completion of the 6-month maintenance phase of the medication trial. CONCLUSION: The DASH-II, while appropriate for assisting in the diagnosis of psychopathology in people with ID, does not appear to monitor changes in problem behaviour as a result of risperidone use as well as the ABC-C. Differences in the frequency of problem behaviour that each measure evaluated and the applicability of using the DASH-II to measure medication effects on problem behaviour are discussed. |
| | |
Authors:
|
M G Valdovinos; J R Zarcone; J A Hellings; G Kim; S R Schroeder |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Journal of intellectual disability research : JIDR Volume: 48 ISSN: 0964-2633 ISO Abbreviation: J Intellect Disabil Res Publication Date: 2004 Jan |
Date Detail:
|
Created Date: 2003-12-16 Completed Date: 2004-05-17 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 9206090 Medline TA: J Intellect Disabil Res Country: England |
Other Details:
|
Languages: eng Pagination: 53-9 Citation Subset: IM |
Affiliation:
|
University of Kansas, KS, USA University of Kansas Medical Center, KS, USA. maria.g.valdovinos@vanderbilt.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antipsychotic Agents
/
therapeutic use* Cross-Over Studies Disabled Persons* Double-Blind Method Humans Mental Disorders / classification, diagnosis*, drug therapy* Questionnaires* Risperidone / therapeutic use* Severity of Illness Index Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
HD02528/HD/NICHD NIH HHS; HD23042/HD/NICHD NIH HHS; HD26927/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 106266-06-2/Risperidone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Behavioural and emotional disturbances in people with Prader-Willi Syndrome.
Next Document: Formal versus informal interventions for challenging behaviour in persons with intellectual disabili...